Source link : https://newshealth.biz/health-news/drug-combo-for-lung-cancer-beats-pembrolizumab-in-first-line-trial/
CHICAGO — Adding an investigational TROP2-targeted antibody-drug conjugate (ADC) to first-line immunotherapy for PD-L1-positive non-small cell lung cancer (NSCLC) reduced the risk of disease progression and may have improved survival as well, interim data from a Chinese phase III study indicated. Over a median follow-up of 10.5 months, sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (Keytruda) cut […]
The post Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-30 20:50:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8